Syndax Pharmaceuticals, Inc. Accrued Liabilities and Other Liabilities
Syndax Pharmaceuticals, Inc. (SNDX) had Accrued Liabilities and Other Liabilities of $94.30 million as of 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Notes › Payables and Accruals
us-gaap:AccruedLiabilitiesAndOtherLiabilities · last filed 2026-08-04
- 2026-06-30: Accrued Liabilities and Other Liabilities $94.30M.
- 2026-03-31: Accrued Liabilities and Other Liabilities $74.84M.
- 2025-12-31: Accrued Liabilities and Other Liabilities $103.06M.
- 2025-09-30: Accrued Liabilities and Other Liabilities $77.11M.
| Period end | Accrued Liabilities and Other Liabilities | Accrued Liabilities and Other Liabilities as first filed |
|---|---|---|
| 2026-06-30 | $94.30M 10-Q · filed 2026-08-04 | |
| 2026-03-31 | $74.84M 10-Q · filed 2026-04-30 | |
| 2025-12-31 | $103.06M 10-Q · filed 2026-08-04 | |
| 2025-09-30 | $77.11M 10-Q · filed 2025-11-03 | |
| 2025-06-30 | $71.07M 10-Q · filed 2025-08-04 | |
| 2025-03-31 | $55.98M 10-Q · filed 2025-05-05 | |
| 2024-12-31 | $60.10M 10-K · filed 2026-02-26 | $59.79M 10-K · filed 2025-03-03 |
| 2024-09-30 | $48.12M 10-Q · filed 2024-11-05 | |
| 2024-06-30 | $26.81M 10-Q · filed 2024-08-01 | |
| 2024-03-31 | $33.40M 10-Q · filed 2024-05-08 | |
| 2023-12-31 | $39.86M 10-K · filed 2025-03-03 | |
| 2023-09-30 | $32.12M 10-Q · filed 2023-11-02 | |
| 2023-06-30 | $17.73M 10-Q · filed 2023-08-03 | |
| 2023-03-31 | $15.21M 10-Q · filed 2023-05-08 | |
| 2022-12-31 | $24.28M 10-K · filed 2024-02-27 | |
| 2022-09-30 | $13.21M 10-Q · filed 2022-11-03 | |
| 2022-06-30 | $16.97M 10-Q · filed 2022-08-08 | |
| 2022-03-31 | $18.42M 10-Q · filed 2022-05-09 | |
| 2021-12-31 | $14.46M 10-K · filed 2023-02-28 | $14.47M 10-K · filed 2022-03-01 |
| 2021-09-30 | $13.73M 10-Q · filed 2021-11-15 | |
| 2021-06-30 | $11.72M 10-Q · filed 2021-08-09 | |
| 2021-03-31 | $11.41M 10-Q · filed 2021-05-11 | |
| 2020-12-31 | $24.28M 10-K · filed 2023-02-28 | $11.25M 10-K · filed 2021-03-12 |
| 2020-09-30 | $9.43M 10-Q · filed 2020-11-05 | |
| 2020-06-30 | $8.69M 10-Q · filed 2020-08-06 | |
| 2020-03-31 | $7.79M 10-Q · filed 2020-05-07 | |
| 2019-12-31 | $10.20M 10-K · filed 2021-03-12 | |
| 2019-09-30 | $9.54M 10-Q · filed 2019-11-07 | |
| 2019-06-30 | $13.17M 10-Q · filed 2019-08-07 | |
| 2019-03-31 | $9.27M 10-Q · filed 2019-05-08 | |
| 2018-12-31 | $13.15M 10-K · filed 2020-03-05 | |
| 2018-09-30 | $12.32M 10-Q · filed 2018-11-05 | |
| 2018-06-30 | $12.48M 10-Q · filed 2018-08-08 | |
| 2018-03-31 | $12.80M 10-Q · filed 2018-05-09 | |
| 2017-12-31 | $11.99M 10-K · filed 2019-03-07 | |
| 2017-09-30 | $10.74M 10-Q · filed 2017-11-08 | |
| 2017-06-30 | $6.92M 10-Q · filed 2017-08-10 | |
| 2017-03-31 | $7.03M 10-Q · filed 2017-05-09 | |
| 2016-12-31 | $6.77M 10-K · filed 2018-03-08 | |
| 2016-09-30 | $5.92M 10-Q · filed 2016-11-14 | |
| 2016-06-30 | $3.75M 10-Q · filed 2016-08-15 | |
| 2016-03-31 | $3.59M 10-Q · filed 2016-05-16 | |
| 2015-12-31 | $2.17M 10-K · filed 2017-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |